Celonic News and Resources

Celonic Group has entered a multi-year commercial manufacturing agreement with LINDIS Biotech to produce catumaxomab, a bispecific monoclonal antibody designed for the treatment of malignant ascites in patients with EpCAM-positive carcinomas. The agreement strengthens Celonic’s role as a CDMO in biologics contract manufacturing. Catumaxomab is a first-in-class therapy